Pharmacokinetics of idarubicin (4-DMDR) with or without cytarabine (ARA-C) in patients (pts) with relapsed leukemia
Publication
, Journal Article
Hancock, C; Niedzwiecki, D; Merke, D
Published in: Proceedings of the American Association for Cancer Research
January 1, 1985
Duke Scholars
Published In
Proceedings of the American Association for Cancer Research
Publication Date
January 1, 1985
Volume
VOL. 26
Citation
APA
Chicago
ICMJE
MLA
NLM
Hancock, C., Niedzwiecki, D., & Merke, D. (1985). Pharmacokinetics of idarubicin (4-DMDR) with or without cytarabine (ARA-C) in patients (pts) with relapsed leukemia. Proceedings of the American Association for Cancer Research, VOL. 26.
Hancock, C., D. Niedzwiecki, and D. Merke. “Pharmacokinetics of idarubicin (4-DMDR) with or without cytarabine (ARA-C) in patients (pts) with relapsed leukemia.” Proceedings of the American Association for Cancer Research VOL. 26 (January 1, 1985).
Hancock C, Niedzwiecki D, Merke D. Pharmacokinetics of idarubicin (4-DMDR) with or without cytarabine (ARA-C) in patients (pts) with relapsed leukemia. Proceedings of the American Association for Cancer Research. 1985 Jan 1;VOL. 26.
Hancock, C., et al. “Pharmacokinetics of idarubicin (4-DMDR) with or without cytarabine (ARA-C) in patients (pts) with relapsed leukemia.” Proceedings of the American Association for Cancer Research, vol. VOL. 26, Jan. 1985.
Hancock C, Niedzwiecki D, Merke D. Pharmacokinetics of idarubicin (4-DMDR) with or without cytarabine (ARA-C) in patients (pts) with relapsed leukemia. Proceedings of the American Association for Cancer Research. 1985 Jan 1;VOL. 26.
Published In
Proceedings of the American Association for Cancer Research
Publication Date
January 1, 1985
Volume
VOL. 26